Go Pro
NYSE:EW

Edwards Lifesciences Q3 2026 Earnings Report

Edwards Lifesciences logo
$85.23 +0.04 (+0.05%)
Closing price 03:59 PM Eastern
Extended Trading
$85.55 +0.32 (+0.37%)
As of 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Edwards Lifesciences EPS Results

Actual EPS
N/A
Consensus EPS
$0.74
Beat/Miss
N/A
One Year Ago EPS
N/A

Edwards Lifesciences Revenue Results

Actual Revenue
N/A
Expected Revenue
$1.68 billion
Beat/Miss
N/A
YoY Revenue Growth
N/A

Edwards Lifesciences Announcement Details

Quarter
Q3 2026
Time
After Market Closes
Conference Call Date
Thursday, October 29, 2026
Conference Call Time
5:00PM ET

Conference Call Resources

Edwards Lifesciences Earnings Headlines

Elon Warns "America Will Go Bankrupt". Trump's Plan Inside.
National debt just crossed 40 trillion dollars, and Elon Musk says America is 1,000% going to go bankrupt without major changes. As former head of the Department of Government Efficiency under President Trump, Musk saw firsthand how looming spending cuts could rattle markets and squeeze 401ks, IRAs, and TSPs. A preserved IRS provision may help everyday investors shield their retirement savings before the next wave of volatility hits.tc pixel
See More Edwards Lifesciences Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Edwards Lifesciences? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Edwards Lifesciences and other key companies, straight to your email.

About Edwards Lifesciences

Edwards Lifesciences (NYSE:EW) is a medical technology company focused on therapies for structural heart disease and other cardiovascular conditions. The company develops and manufactures heart valve replacement and repair technologies, including transcatheter aortic valve replacement systems, surgical heart valves, transcatheter mitral and tricuspid therapies, and related delivery systems and accessories.

Founded in 1958 by engineer Miles “Lowell” Edwards, the company helped pioneer artificial heart valves and has played a significant role in the development of transcatheter valve replacement. Its products are used by hospitals and heart specialists to treat conditions such as aortic stenosis and other heart valve disorders, providing alternatives to traditional open-heart surgery for certain patients.

Edwards Lifesciences serves healthcare providers and patients in the United States and international markets across Europe, Asia-Pacific, and other regions. The company is headquartered in Irvine, California, and is led by President and Chief Executive Officer Bernard Zovighian.

View Edwards Lifesciences Profile